IDO1 and neoplasm: Therefore, IDO/TDO-blocking immunotherapy mediated by CY1-4 may be a promising strategy to reduce tumor immune escape, overcome the deficiency of IDO inhibitors in clinical trials, and expand the application scope of cancer treatment.